Kura Oncology, Inc. (NASDAQ:KURA) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 532,367 shares, a decline of 27.9% from the August 15th total of 738,139 shares. Based on an average daily volume of 188,118 shares, the short-interest ratio is currently 2.8 days. Currently, 2.5% of the shares of the stock are short sold.

Kura Oncology (KURA) opened at 12.95 on Friday. The company has a 50-day moving average of $8.37 and a 200 day moving average of $8.90. The stock’s market capitalization is $258.84 million. Kura Oncology has a 12 month low of $4.00 and a 12 month high of $13.80.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Monday, August 7th. The company reported ($0.40) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.03. On average, equities research analysts anticipate that Kura Oncology will post ($1.53) earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new stake in Kura Oncology in the 1st quarter valued at $533,000. Renaissance Technologies LLC increased its holdings in Kura Oncology by 158.8% in the 1st quarter. Renaissance Technologies LLC now owns 79,200 shares of the company’s stock valued at $697,000 after acquiring an additional 48,600 shares during the last quarter. Alethea Capital Management LLC increased its holdings in Kura Oncology by 128.1% in the 2nd quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock valued at $1,798,000 after acquiring an additional 108,577 shares during the last quarter. Nationwide Fund Advisors bought a new stake in Kura Oncology in the 1st quarter valued at $136,000. Finally, Segantii Capital Management Ltd bought a new stake in Kura Oncology in the 1st quarter valued at $120,000. Institutional investors own 39.07% of the company’s stock.

A number of research analysts have recently commented on the stock. Leerink Swann restated an “outperform” rating and set a $18.00 price target (up from $16.00) on shares of Kura Oncology in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Friday. Citigroup Inc. set a $13.00 price target on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday, August 8th. ValuEngine upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $16.00 price target on shares of Kura Oncology in a research report on Wednesday, June 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $15.60.

ILLEGAL ACTIVITY WARNING: “Kura Oncology, Inc. (KURA) Short Interest Update” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/17/kura-oncology-inc-kura-short-interest-update.html.

Kura Oncology Company Profile

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.